Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer
2011

MR-1: A New Biomarker for Ovarian Cancer

Sample size: 51 publication Evidence: moderate

Author Information

Author(s): Lu Renquan, Sun Min, Feng Jingjing, Gao Xiang, Guo Lin

Primary Institution: Fudan University, Shanghai, China

Hypothesis

MR-1 may play a role in the development and progression of ovarian cancer, probably by promoting cell proliferation and invasion.

Conclusion

MR-1 may be a biomarker for diagnosis of ovarian cancer and could be useful for monitoring the effects of anti-cancer therapies.

Supporting Evidence

  • MR-1 was overexpressed in ovarian cancer tissues and SKOV3 cells.
  • 293T cells overexpressing MR-1 showed enhanced cellular spread and invasion.
  • Knockdown of MR-1 expression inhibited cell adhesion and invasion.
  • Treatment with anti-cancer drugs decreased MR-1 expression in cancer cells.

Takeaway

MR-1 is a protein that helps ovarian cancer cells grow and spread. If we can target it, we might be able to help treat ovarian cancer better.

Methodology

The study used RT-PCR, quantitative real-time PCR, immunohistochemical analysis, and cell line experiments to assess MR-1 expression and its effects on cell behavior.

Limitations

Further studies are needed to clarify whether MR-1 is an early diagnostic marker for ovarian cancer and to develop its full therapeutic potential.

Participant Demographics

26 ovarian cancer patients (aged 20-58 years) and 25 controls with benign ovarian disease (aged 23-55 years).

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-11-270

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication